menu

Applying Shared Decision-Making to ER+/HER2- Metastatic Breast Cancer Care

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Selecting Therapy for ER+/HER2- Metastatic Breast Cancer: Key Factors to Consider

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Sponsored by

  • Overview

    From disease-related factors to the latest clinical trial data, there’s a lot to consider when selecting a therapy for patients with ER+/HER2- metastatic breast cancer. Here with Dr. Charles Turck to break down the key factors that can guide our treatment selections is breast medical oncologist Dr. Megan Kruse from the Cleveland Clinic in Ohio.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Sponsored by

  • Overview

    From disease-related factors to the latest clinical trial data, there’s a lot to consider when selecting a therapy for patients with ER+/HER2- metastatic breast cancer. Here with Dr. Charles Turck to break down the key factors that can guide our treatment selections is breast medical oncologist Dr. Megan Kruse from the Cleveland Clinic in Ohio.

Facebook Comments

Schedule29 Mar 2024